Pdt Partners, LLC Precision Biosciences Inc Transaction History

Pdt Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.15 - $3.34 $25,335 - $73,583	-22,031 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.96 - $7.76 $648 - $1,699	-219 Reduced 0.98%	22,031 $68,000
Q4 2021 Feb 14, 2022	SELL	$7.4 - $11.66 $313,752 - $494,372	-42,399 Reduced 65.58%	22,250 $165,000
Q3 2021 Nov 15, 2021	SELL	$9.18 - $14.15 $384,192 - $592,191	-41,851 Reduced 39.3%	64,649 $746,000
Q2 2021 Aug 16, 2021	SELL	$8.07 - $12.52 $188,660 - $292,692	-23,378 Reduced 18.0%	106,500 $1.33 Million

Q1 2021 May 17, 2021	BUY	$8.57 - $15.79 $923,657 - $1.7 Million	107,778 Added 487.68%	129,878 $1.34 Million
Q4 2020 Feb 16, 2021	SELL	$5.98 - $12.47 $14,866 - $31,000	-2,486 Reduced 10.11%	22,100 $184,000
Q3 2020 Nov 16, 2020	SELL	$4.65 - $8.73 $29,746 - $55,845	-6,397 Reduced 20.65%	24,586 $151,000
Q2 2020 Aug 14, 2020	SELL	$4.66 - $8.7 $23,183 - $43,282	-4,975 Reduced 13.84%	30,983 $258,000
Q1 2020 May 15, 2020	BUY	$5.05 - $15.01 $181,587 - $539,729	35,958 New	35,958 $217,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $1.08B
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.